Review
Immunology
Abolfazl Maghrouni, Maryam Givari, Mohammad Jalili-Nik, Hamid Mollazadeh, Bahram Bibak, Mohammad Montazami Sadeghi, Amir R. Afshari, Thomas P. Johnston, Amirhossein Sahebkar
Summary: GBM, an immunosuppressive brain tumor, remains difficult to manage despite current treatments. Immunotherapy, particularly checkpoint inhibitors, has potential for GBM treatment but faces challenges due to the tumor's immunosuppressive microenvironment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Immunology
Rilan Bai, Jiuwei Cui
Summary: Antibodies targeting PD-1/PD-L1 have been considered breakthrough therapies for cancer. In addition to T cell-driven immune responses, blocking PD-1/PD-L1 may also enhance the function and activity of NK cells, which are often overlooked in previous studies.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Ru-Yue Chen, Yun Zhu, Yun-Yan Shen, Qin-Ying Xu, Han-Yun Tang, Ning-Xun Cui, Lu Jiang, Xiao-Mei Dai, Wei-Qing Chen, Qiang Lin, Xiao-Zhong Li
Summary: Programmed cell death 1 receptor (PD-1) and its ligands play a crucial role in immune tolerance, immune homeostasis, and immunosuppression. The PD-1 pathway has been implicated in various diseases, including cancer and autoimmune diseases, and PD-1 blockades have been approved for cancer treatment. This comprehensive review focuses on the structure and expression of PD-1, PD-L1, and PD-L2, the diverse biological functions of PD-1 signaling in health and immune-related diseases, and the immune-related adverse events associated with PD-1 and PD-L1 inhibitors.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Ruoyu Miao, Jennifer Swank, Dan Melzer, Steven Ludlow, Leah Clark, Molly Finger, Damon R. Reed, Mihaela Druta, Andrew S. Brohl
Summary: The use of anti-PD1 immunotherapy has shown significant efficacy in advanced sarcomas with cutaneous primary site. It is a stronger predictor of response than histologic subtype and should be considered in treatment guidelines and clinical trial design.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Oncology
David Johnson, Brigette B. Y. Ma
Summary: The upregulation of the PD-1/PD-L1 pathway is a possible immune-evasion mechanism in Epstein-Barr virus-associated nasopharyngeal cancer (NPC). Therapeutic targeting of this pathway is actively researched in NPC, with multiple monoclonal antibodies currently under evaluation in clinical settings. Combinatorial strategies involving cytotoxic chemotherapy, radiotherapy, and other immunotherapeutic agents are also being explored in clinical trials for NPC.
Review
Chemistry, Medicinal
Anica Hoegner, Peter Thuss-Patience
Summary: Immune checkpoint inhibitors have shown significant efficacy in the treatment of esophago-gastric carcinoma, improving overall survival in different treatment stages. PD-1 inhibitors in first and second-line treatments have demonstrated significant benefits and are likely to receive further approvals.
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
James Godfrey, Xiufen Chen, Nicole Sunseri, Alan Cooper, Jovian Yu, Arina Varlamova, Dmitry Zarubin, Yuriy Popov, Connor Jacobson, Ekaterina Postovalova, Zhongmin Xiang, Krystle Nomie, Aleksander Bagaev, Girish Venkataraman, Yuanyuan Zha, Sravya Tumuluru, Sonali M. Smith, Justin P. Kline
Summary: This study reveals that TIGIT is widely expressed in lymphoma-infiltrating T cells (LITs) and frequently coexpressed with PD-1. In DLBCL, TIGIT(+) LITs often have significant contact with malignant B cells and exhibit dysfunctional cytokine production upon restimulation. In mouse experiments, combined blockade of PD-1 and TIGIT leads to complete rejection of lymphomas and significantly prolongs survival compared to monoblockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Nanoscience & Nanotechnology
Guanping He, Yajun Shuai, Yong Hai, Tao Yang, Xiaoyu Pan, Yuzeng Liu, Xianglong Meng, Honghao Yang, Mingying Yang, Chuanbin Mao
Summary: This study used a new nanomaterial for photothermal immunotherapy to successfully eradicate tumors, demonstrating its potential in treating metastatic osteosarcoma.
MATERIALS TODAY NANO
(2022)
Article
Immunology
Poyee Lau, Guanxiong Zhang, Shuang Zhao, Long Liang, Hailun Zhang, Guowei Zhou, Mien-Chie Hung, Xiang Chen, Hong Liu
Summary: This study reveals the important role of SPHK1 in tumor immunity and shows that its inhibition can suppress tumor growth and promote antitumor immunity. Additionally, SPHK1 and MTA3 are identified as biological markers for predicting the efficacy of anti-PD-1 mAb therapy in melanoma patients.
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Review
Immunology
Jianqiong Yin, Yuanjun Wu, Xue Yang, Lu Gan, Jianxin Xue
Summary: Immune checkpoint inhibitors (ICIs) are drugs used to treat non-small-cell lung cancer by enhancing the function of T cells and producing long-lasting antitumor effects. However, ICIs can cause immune-related adverse events (irAEs), including severe pneumonia. Currently, the diagnosis and mechanisms of checkpoint inhibitor pneumonitis (CIP) are not well understood.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Federica Costa, Rosanna Vescovini, Valentina Marchica, Paola Storti, Laura Notarfranchi, Benedetta Dalla Palma, Denise Toscani, Jessica Burroughs-Garcia, Maria Teresa Catarozzo, Gabriella Sammarelli, Nicola Giuliani
Summary: The study found that MM and SMM patients share a similar PD-L1/PD-1 bone marrow immune profile, suggesting that SMM patients could be an interesting target for PD-L1/PD-1 inhibition therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Keywan Mortezaee, Jamal Majidpoor
Summary: This review discusses the potential of using ILs and IL-targeting drugs in combination with ICI in cancer immunotherapy, and describes recent advances in the field using PEGylated ILs and fusion proteins. The key focus in this area is to reduce adverse events and increase the efficacy and durability of combination therapy.
Review
Medicine, General & Internal
Piaohong Chen, Jianwei Li, Huiwen Tan
Summary: Immune checkpoint inhibitors (ICIs) are a novel class of antitumor drugs that enhance T cell activity by blocking immune checkpoints from binding to their ligands. However, ICIs can disrupt T cell immune tolerance to self-antigens, leading to a series of immune-related adverse events (irAEs). Immune checkpoint inhibitor-induced hypophysitis (IH) is a relatively uncommon irAE that is difficult to diagnose accurately due to non-specific clinical manifestations. This article summarizes the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of IH.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio
Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
